DK2246321T3 - Rasagilinformulering med forsinket frisætning - Google Patents

Rasagilinformulering med forsinket frisætning

Info

Publication number: DK2246321T3
Authority: DK; Denmark
Prior art keywords: delayed release; release rasagiline; formulation; rasagiline formulation; delayed
Prior art date: 2009-01-23

Application number

DK10166534.7T

Other languages

English (en)

Inventor

Muhammad Safadi

Daniella Licht

Rachel Cohen

Anton Frenkel

Marina Zholkovsky

Tamas Koltai

Original Assignee

Teva Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-01-23

Filing date

2010-01-22

Publication date

2011-11-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42354337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2246321(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-01-22 Application filed by Teva Pharma filed Critical Teva Pharma

2010-01-22 Priority claimed from EP10151462A external-priority patent/EP2218444A3/en

2011-11-21 Application granted granted Critical

2011-11-21 Publication of DK2246321T3 publication Critical patent/DK2246321T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Cardiology (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK10166534.7T 2009-01-23 2010-01-22 Rasagilinformulering med forsinket frisætning DK2246321T3 (da)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US20583309P	2009-01-23	2009-01-23
US12/455,976 US8080584B2 (en)	2009-01-23	2009-06-09	Delayed release rasagiline citrate formulation
US12/456,001 US20100189791A1 (en)	2009-01-23	2009-06-09	Delayed release rasagiline malate formulation
US12/456,029 US20100189790A1 (en)	2009-01-23	2009-06-09	Delayed release rasagiline formulation
US12/456,031 US20100189788A1 (en)	2009-01-23	2009-06-09	Delayed release rasagiline base formulation
US12/689,044 US7855233B2 (en)	2009-01-23	2010-01-18	Citrate salt of Rasagiline
EP10151462A EP2218444A3 (en)	2009-01-23	2010-01-22	Delayed release rasagiline formulation

Publications (1)

Publication Number	Publication Date
DK2246321T3 true DK2246321T3 (da)	2011-11-21

Family

ID=42354337

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK10166534.7T DK2246321T3 (da)	2009-01-23	2010-01-22	Rasagilinformulering med forsinket frisætning
DK10186379.3T DK2308477T3 (da)	2009-01-23	2010-01-22	Rasagilinformulering med forsinket frisætning
DKBA201100050U DK201100050U4 (da)	2009-01-23	2011-03-11	Rasagilinformulering med forsinket frigivelse

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK10186379.3T DK2308477T3 (da)	2009-01-23	2010-01-22	Rasagilinformulering med forsinket frisætning
DKBA201100050U DK201100050U4 (da)	2009-01-23	2011-03-11	Rasagilinformulering med forsinket frigivelse

Country Status (22)

Country	Link
US (9)	US20100189788A1 (da)
EP (3)	EP2381767B1 (da)
JP (2)	JP5774495B2 (da)
CN (1)	CN102333442B (da)
AR (1)	AR075148A1 (da)
AT (3)	ATE556703T1 (da)
AU (1)	AU2010206970B2 (da)
CA (3)	CA2799515A1 (da)
CY (2)	CY1112486T1 (da)
CZ (1)	CZ22819U1 (da)
DE (1)	DE202010017129U1 (da)
DK (3)	DK2246321T3 (da)
EA (1)	EA029262B1 (da)
ES (3)	ES2564317T3 (da)
HK (1)	HK1150308A1 (da)
HR (2)	HRP20110745T1 (da)
IL (1)	IL214220A (da)
PL (2)	PL2308477T3 (da)
PT (2)	PT2246321E (da)
RS (2)	RS52033B (da)
SI (2)	SI2246321T1 (da)
WO (1)	WO2010085354A1 (da)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2574925A1 (en) *	2004-07-26	2006-02-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical dosage forms including rasagiline
ES2371883T3 (es) *	2004-11-24	2012-01-11	Teva Pharmaceutical Industries Ltd.	Composiciones de rasagilina de disgregación oral.
JP5701485B2 (ja) *	2006-02-21	2015-04-15	テバファーマシューティカルインダストリーズリミティド	多系統萎縮症の治療のためのラサギリンの使用
JP5769923B2 (ja) *	2006-04-03	2015-08-26	テバファーマシューティカルインダストリーズリミティド	レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
EA016820B1 (ru) *	2006-12-14	2012-07-30	Тева Фармасьютикал Индастриз, Лтд.	Кристаллическое твердое основание разагилина
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
WO2009032273A1 (en) *	2007-09-05	2009-03-12	Teva Pharmaceutical Industries, Ltd.	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
CN101909438A (zh) *	2008-01-11	2010-12-08	泰华制药工业有限公司	雷沙吉兰制剂、其制备及用途
US20100008983A1 (en) *	2008-06-10	2010-01-14	Muhammad Safadi	Rasagiline soft gelatin capsules
AU2009258151A1 (en) *	2008-06-13	2009-12-17	Teva Pharmaceutical Industries, Ltd.	Rasagiline for Parkinson's disease modification
AU2009260728B2 (en) *	2008-06-19	2015-01-29	Teva Pharmaceutical Industries, Ltd.	Process for preparing and drying solid rasagiline base
CA2727021A1 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Process for purifying rasagiline base
US20100189788A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline base formulation
ITPR20090047A1 (it) *	2009-06-16	2010-12-17	Agricola Cerasaro S S Soc	Procedimento per la produzione di un trito o crema di aglio e trito o crema di aglio cosi' ottenuta
CA2767592A1 (en)	2009-07-09	2011-01-13	Ratiopharm Gmbh	Salts of rasagiline and pharmaceutical preparations thereof
US9675566B2 (en)	2009-07-16	2017-06-13	Pathologica Llc	Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
WO2011042812A1 (en) *	2009-10-09	2011-04-14	Stefan Lorenzl	Use of rasagiline for the treatment of progressive supranuclear palsy
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
EP2515891A4 (en) *	2009-12-22	2013-06-05	Teva Pharma	3-keto-N-propargyl-1-aminoindan
JP2013537530A (ja)	2010-07-27	2013-10-03	テバファーマシューティカルインダストリーズリミティド	ラサギリンシトレートの分散物
US8569379B2 (en)	2010-07-27	2013-10-29	Teva Pharmaceutical Industries Ltd.	Use of rasagiline for the treatment of olfactory dysfunction
CA2816104A1 (en) *	2010-10-26	2012-05-03	Teva Pharmaceutical Industries Ltd.	Deuterium enriched rasagiline
HU231054B1 (hu) *	2010-11-18	2020-04-28	Egis Gyógyszergyár Nyrt.	Gyógyászati készítmény előállítására alkalmazható új sók
PT2665471T (pt)	2011-01-19	2018-03-21	Pathologica Llc	Formas de dosagem farmacêutica orais de libertação controlada que compreendem mgbg
MX2014004196A (es) *	2011-10-10	2014-05-28	Teva Pharma	Citramida de rasagilina.
CA2851433A1 (en) *	2011-10-10	2013-04-18	Teva Pharmaceutical Industries Ltd.	R(+)-n-methyl-propargyl-aminoindan
BR112014008555A2 (pt)	2011-10-10	2017-04-18	Teva Pharma	r(+)-n-formil-propargil-aminoindano
WO2013139387A1 (en)	2012-03-21	2013-09-26	Synthon Bv	Stabilized pharmaceutical compositions comprising rasagiline salts
MX2015002062A (es)	2012-08-17	2015-06-05	Teva Pharma	Formulaciones parenterales de rasagilina.
JP2014050039A (ja) *	2012-09-03	2014-03-17	Sony Corp	画像処理装置、画像処理方法及びコンピュータプログラム
CN109432073A (zh)	2013-01-08	2019-03-08	帕萨罗杰卡有限公司	Mgbg在制备治疗或预防进行性ms及其进展的药物中的用途
JP6173098B2 (ja)	2013-07-30	2017-08-02	キヤノン株式会社	光学機器
JP5897196B1 (ja)	2015-10-05	2016-03-30	大同化成工業株式会社	糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法
CN107049985B (zh) *	2017-06-07	2020-06-19	广州帝奇医药技术有限公司	一种抗帕金森病药物的长效缓释制剂及其制备方法
CN109028765A (zh) *	2018-07-02	2018-12-18	无锡富泽药业有限公司	一种盐酸替罗非班的干燥方法
CN109832262A (zh) *	2019-01-25	2019-06-04	袁隆平农业高科技股份有限公司	活体植物保存方法
CN114469902B (zh)	2020-10-23	2024-10-29	上海上药中西制药有限公司	雷沙吉兰或其药用盐舌下膜剂及其制备方法、应用
CN115400090A (zh) *	2022-10-09	2022-11-29	北京新领先医药科技发展有限公司	一种雷沙吉兰的口崩片组合物及其制备方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US761917A (en) *	1903-02-11	1904-06-07	Alphonse King	Telegraph-transmitter.
US5744500A (en)	1990-01-03	1998-04-28	Teva Pharmaceutical Industries, Ltd.	Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en)	1990-01-03	1994-06-24	Teva Pharma	R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL112819A (en) *	1991-10-16	2001-11-25	Teva Pharma	Fluorinated 1-aminoindan compounds and a process for their preparation
IL111240A (en)	1993-10-18	2001-10-31	Teva Pharma	Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them
IL115357A (en)	1995-09-20	2000-01-31	Teva Pharma	Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols
US5663415A (en) *	1996-06-28	1997-09-02	Jame Fine Chemicals, Inc.	Process for preparing antihistamine tannates
IL118836A (en) *	1996-07-11	2001-01-11	Teva Pharma	Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
EP1535902B1 (en) *	1996-12-18	2007-11-07	Teva Pharmaceutical Industries, Ltd.	Aminoindan derivatives
WO1998040102A1 (en)	1997-03-13	1998-09-17	The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin	Cytoprotective agents comprising monoamine oxidase inhibitors
US6548706B2 (en) *	1999-12-23	2003-04-15	Aerojet Fine Chemicals Llc	Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines
DE10041478A1 (de)	2000-08-24	2002-03-14	Sanol Arznei Schwarz Gmbh	Neue pharmazeutische Zusammensetzung
US20070197484A1 (en) *	2001-05-03	2007-08-23	Ching Song	Method of treating disorder related to high cholesterol concentration
EP1390366B1 (en)	2001-05-14	2005-08-31	Pfizer Products Inc.	The citrate salt of 5,8,14,-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaene
GT200200234A (es)	2001-12-06	2003-06-27		Compuestos cristalinos novedosos
JP4165882B2 (ja)	2001-12-07	2008-10-15	ファイザー・プロダクツ・インク	治療用化合物のクエン酸塩及びその医薬組成物
US7118765B2 (en)	2001-12-17	2006-10-10	Spi Pharma, Inc.	Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms
ES2432117T3 (es) *	2002-11-15	2013-11-29	Teva Pharmaceutical Industries Limited	Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
AR044007A1 (es)	2003-04-11	2005-08-24	Newron Pharmaceuticals Inc	Metodos para el tratamiento de la enfermedad de parkinson
US20060177507A1 (en) *	2003-05-22	2006-08-10	Joaquina Faour	Controlled release device containing lercanidipine
PE20051096A1 (es)	2004-02-04	2006-01-23	Novartis Ag	Formas de sal de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-ilamino)fenil]-benzamida
EP1720527A2 (en) *	2004-03-03	2006-11-15	Teva Pharmaceutical Industries Ltd	A stable pharmaceutical composition comprising an acid labile drug
US7145005B2 (en)	2004-05-12	2006-12-05	Abbott Laboratories	2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation
CA2574925A1 (en) *	2004-07-26	2006-02-09	Teva Pharmaceutical Industries Ltd.	Pharmaceutical dosage forms including rasagiline
MX2007001058A (es) *	2004-07-26	2007-04-16	Teva Pharma	Formas de dosificacion con tableta nucleo recubierta entericamente.
US20060069060A1 (en)	2004-09-27	2006-03-30	Sanjeev Redkar	Salts of decitabine
ES2371883T3 (es)	2004-11-24	2012-01-11	Teva Pharmaceutical Industries Ltd.	Composiciones de rasagilina de disgregación oral.
RU2389482C2 (ru)	2004-11-24	2010-05-20	Тева Фармасьютикал Индастриз, Лтд.	Композиции разагилина, распадающиеся в ротовой полости
RS52867B (en)	2005-02-17	2013-12-31	Teva Pharmaceutical Industries Ltd.	GLATIRAMER ACETATOM AND RAZAGILIN COMBINED THERAPY FOR MULTIPLE SCLEROSIS
EP1848402B2 (en)	2005-02-23	2019-02-20	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations of improved content uniformity
US8349951B2 (en)	2005-05-31	2013-01-08	Prc Desoto International, Inc.	Polythioether polymers and curable compositions containing them
US20070078172A1 (en) *	2005-06-16	2007-04-05	Jenrin Discovery	Mao-b inhibitors useful for treating obesity
GB0514593D0 (en)	2005-07-15	2005-08-24	Davy Process Techn Ltd	Process
ES2328407T3 (es)	2005-09-19	2009-11-12	Pfizer Products Incorporated	Formas salinas solidas de una 2-indolinona sustituida con pirrol.
FR2891459B1 (fr) *	2005-09-30	2007-12-28	Flamel Technologies Sa	Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
JP2009521402A (ja) *	2005-11-17	2009-06-04	テバファーマシューティカルインダストリーズリミティド	プロパルギル化アミノインダンの分離のための方法
HUP0501084A2 (en)	2005-11-23	2008-05-28	Richter Gedeon Nyrt	New pharmaceutical compositions of high effectivity
US7572834B1 (en) *	2005-12-06	2009-08-11	Teva Pharmaceutical Industries, Ltd.	Rasagiline formulations and processes for their preparation
SA07280004B1 (ar)	2006-02-02	2011-10-29	استرازينيكا ايه بي	ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات
US20080027087A1 (en)	2006-02-21	2008-01-31	Ampla Pharmaceuticals, Inc.	CB1 antagonists and inverse agonists
JP5701485B2 (ja) *	2006-02-21	2015-04-15	テバファーマシューティカルインダストリーズリミティド	多系統萎縮症の治療のためのラサギリンの使用
CN101032474B (zh) *	2006-03-06	2011-02-16	重庆医药工业研究院有限责任公司	一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法
JP5769923B2 (ja)	2006-04-03	2015-08-26	テバファーマシューティカルインダストリーズリミティド	レストレスレッグス症候群の治療のためのラサギリンの使用
WO2008010768A1 (en)	2006-07-17	2008-01-24	Cereuscience Ab	Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method
EP1892233A1 (de)	2006-08-18	2008-02-27	Ratiopharm GmbH	Neue Salze des Wirkstoffs Rasagilin
CN1911211B (zh) *	2006-08-25	2010-04-14	重庆医药工业研究院有限责任公司	雷沙吉兰口服固体制剂
CN100542524C (zh) *	2006-09-29	2009-09-23	北京德众万全药物技术开发有限公司	一种含有雷沙吉兰的药用组合物
AR063983A1 (es) *	2006-11-28	2009-03-04	Wyeth Corp	Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada
US8524695B2 (en) *	2006-12-14	2013-09-03	Knopp Neurosciences, Inc.	Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
EA016820B1 (ru) *	2006-12-14	2012-07-30	Тева Фармасьютикал Индастриз, Лтд.	Кристаллическое твердое основание разагилина
EP2101570B1 (en)	2006-12-14	2013-02-13	Teva Pharmaceutical Industries, Ltd.	Tannate salt of rasagiline
US7949403B2 (en)	2007-02-27	2011-05-24	Accelerated Care Plus Corp.	Electrical stimulation device and method for the treatment of neurological disorders
WO2008139984A1 (en)	2007-04-26	2008-11-20	Eisai R & D Management Co., Ltd.	Cinnamide compounds for dementia
EP1987816A1 (de) *	2007-04-30	2008-11-05	Ratiopharm GmbH	Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
JP5577012B2 (ja)	2007-05-03	2014-08-20	株式会社カネカ	多層基板およびその製造方法
WO2009032273A1 (en) *	2007-09-05	2009-03-12	Teva Pharmaceutical Industries, Ltd.	Method of treating glaucoma using rasagiline
US8188149B2 (en) *	2007-09-17	2012-05-29	Teva Pharmaceutical Industries, Ltd.	Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
JP5425806B2 (ja)	2007-12-24	2014-02-26	シプラ・リミテッド	プロパルギル化アミノインダン誘導体の合成方法
CN101909438A (zh) *	2008-01-11	2010-12-08	泰华制药工业有限公司	雷沙吉兰制剂、其制备及用途
US20090247537A1 (en)	2008-03-25	2009-10-01	William Dale Overfield	Methods for preventing or treating bruxism using dopaminergic agents
US20110117200A1 (en)	2008-03-31	2011-05-19	Actavis Group Ptc Ehf	Rasagiline mesylate particles and process for the preparation thereof
US20100008983A1 (en)	2008-06-10	2010-01-14	Muhammad Safadi	Rasagiline soft gelatin capsules
AU2009258151A1 (en)	2008-06-13	2009-12-17	Teva Pharmaceutical Industries, Ltd.	Rasagiline for Parkinson's disease modification
CA2727021A1 (en) *	2008-06-19	2009-12-23	Teva Pharmaceutical Industries Ltd.	Process for purifying rasagiline base
AU2009260728B2 (en)	2008-06-19	2015-01-29	Teva Pharmaceutical Industries, Ltd.	Process for preparing and drying solid rasagiline base
CN101606923B (zh)	2008-06-20	2013-01-09	重庆医药工业研究院有限责任公司	一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法
EA201170181A1 (ru)	2008-07-11	2011-08-30	Синтон Бв	Полиморфные формы разагилина гидрохлорида
US20100041920A1 (en)	2008-07-18	2010-02-18	Stephen Benedict David Winter	New salt forms of an aminoindan derivative
US20100029987A1 (en) *	2008-07-29	2010-02-04	Dipharma Francis S.R.I.	Crystalline Form of Rasagiline and Process for the Preparation Thereof
WO2010013048A1 (en)	2008-07-30	2010-02-04	Generics [Uk] Limited	Polymorphic form of rasagiline mesylate
EP2181980A1 (en)	2008-10-28	2010-05-05	Chemo Ibérica, S.A.	A process for the preparation of (R)-1-aminoindanes
DE102008064061A1 (de)	2008-12-19	2010-06-24	Ratiopharm Gmbh	Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189788A1 (en) *	2009-01-23	2010-07-29	Teva Pharmaceutical Industries, Ltd.	Delayed release rasagiline base formulation
CA2767592A1 (en) *	2009-07-09	2011-01-13	Ratiopharm Gmbh	Salts of rasagiline and pharmaceutical preparations thereof
US20110015274A1 (en)	2009-07-20	2011-01-20	Ester Masllorens Llinas	Form of an aminoindan mesylate derivative
WO2011010324A1 (en)	2009-07-23	2011-01-27	Alkem Laboratories Ltd.	Oral pharmaceutical composition of rasagiline and process for preparing thereof
WO2011042812A1 (en)	2009-10-09	2011-04-14	Stefan Lorenzl	Use of rasagiline for the treatment of progressive supranuclear palsy
CN102048717B (zh) *	2009-10-29	2014-02-19	重庆医药工业研究院有限责任公司	一种稳定的雷沙吉兰组合物
EP2515891A4 (en) *	2009-12-22	2013-06-05	Teva Pharma	3-keto-N-propargyl-1-aminoindan

2009
- 2009-06-09 US US12/456,031 patent/US20100189788A1/en not_active Abandoned
- 2009-06-09 US US12/456,029 patent/US20100189790A1/en not_active Abandoned
- 2009-06-09 US US12/456,001 patent/US20100189791A1/en not_active Abandoned
- 2009-06-09 US US12/455,976 patent/US8080584B2/en not_active Expired - Fee Related
2010
- 2010-01-18 US US12/689,044 patent/US7855233B2/en not_active Expired - Fee Related
- 2010-01-21 WO PCT/US2010/000174 patent/WO2010085354A1/en active Application Filing
- 2010-01-21 ES ES10733731.3T patent/ES2564317T3/es active Active
- 2010-01-21 CA CA2799515A patent/CA2799515A1/en not_active Abandoned
- 2010-01-21 EP EP10733731.3A patent/EP2381767B1/en active Active
- 2010-01-21 JP JP2011547964A patent/JP5774495B2/ja not_active Expired - Fee Related
- 2010-01-21 US US13/145,989 patent/US20120003310A1/en not_active Abandoned
- 2010-01-21 AU AU2010206970A patent/AU2010206970B2/en not_active Ceased
- 2010-01-21 EA EA201170962A patent/EA029262B1/ru not_active IP Right Cessation
- 2010-01-21 CA CA2713292A patent/CA2713292C/en not_active Expired - Fee Related
- 2010-01-21 CA CA2727899A patent/CA2727899C/en not_active Expired - Fee Related
- 2010-01-21 CN CN201080009551.4A patent/CN102333442B/zh not_active Expired - Fee Related
- 2010-01-22 SI SI201030008T patent/SI2246321T1/sl unknown
- 2010-01-22 DK DK10166534.7T patent/DK2246321T3/da active
- 2010-01-22 PT PT10166534T patent/PT2246321E/pt unknown
- 2010-01-22 AR ARP100100139A patent/AR075148A1/es unknown
- 2010-01-22 SI SI201030050T patent/SI2308477T1/sl unknown
- 2010-01-22 PL PL10186379T patent/PL2308477T3/pl unknown
- 2010-01-22 PT PT10186379T patent/PT2308477E/pt unknown
- 2010-01-22 ES ES10186379T patent/ES2389889T3/es active Active
- 2010-01-22 EP EP10166534A patent/EP2246321B1/en active Active
- 2010-01-22 EP EP10186379A patent/EP2308477B1/en active Active
- 2010-01-22 AT AT10186379T patent/ATE556703T1/de active
- 2010-01-22 RS RS20110487A patent/RS52033B/en unknown
- 2010-01-22 ES ES10166534T patent/ES2370980T3/es active Active
- 2010-01-22 RS RS20120337A patent/RS52421B/en unknown
- 2010-01-22 AT ATGM76/2011U patent/AT12508U1/de not_active IP Right Cessation
- 2010-01-22 PL PL10166534T patent/PL2246321T3/pl unknown
- 2010-01-22 DK DK10186379.3T patent/DK2308477T3/da active
- 2010-01-22 DE DE202010017129U patent/DE202010017129U1/de not_active Expired - Lifetime
- 2010-01-22 AT AT10166534T patent/ATE518527T1/de active
2011
- 2011-01-27 CZ CZ201123855U patent/CZ22819U1/cs not_active IP Right Cessation
- 2011-03-11 DK DKBA201100050U patent/DK201100050U4/da not_active IP Right Cessation
- 2011-05-03 HK HK11104418.3A patent/HK1150308A1/xx not_active IP Right Cessation
- 2011-07-20 IL IL214220A patent/IL214220A/en not_active IP Right Cessation
- 2011-10-13 HR HR20110745T patent/HRP20110745T1/hr unknown
- 2011-10-31 CY CY20111101033T patent/CY1112486T1/el unknown
- 2011-12-23 US US13/336,609 patent/US20120100189A1/en not_active Abandoned
2012
- 2012-06-29 US US13/538,715 patent/US20120263789A1/en not_active Abandoned
- 2012-07-31 CY CY20121100679T patent/CY1112954T1/el unknown
- 2012-08-02 HR HRP20120633AT patent/HRP20120633T1/hr unknown
2013
- 2013-12-23 US US14/139,212 patent/US20140186514A1/en not_active Abandoned
2014
- 2014-11-26 JP JP2014239283A patent/JP2015091813A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US20100189788A1 (en)	2010-07-29
PT2246321E (pt)	2011-10-19
EP2308477B1 (en)	2012-05-09
HRP20120633T1 (hr)	2012-09-30
CN102333442B (zh)	2015-08-19
AT12508U1 (de)	2012-06-15
CY1112486T1 (el)	2015-12-09
CN102333442A (zh)	2012-01-25
US20120003310A1 (en)	2012-01-05
AU2010206970B2 (en)	2016-05-05
PL2308477T3 (pl)	2012-10-31
SI2246321T1 (sl)	2011-11-30
US8080584B2 (en)	2011-12-20
EP2381767A4 (en)	2014-12-24
ES2370980T3 (es)	2011-12-26
US20100189791A1 (en)	2010-07-29
ES2389889T3 (es)	2012-11-02
DK201100050U1 (da)	2011-07-08
IL214220A (en)	2016-03-31
AU2010206970A1 (en)	2011-08-18
ES2564317T3 (es)	2016-03-21
ATE556703T1 (de)	2012-05-15
CA2713292A1 (en)	2010-11-23
JP2012515775A (ja)	2012-07-12
DK201100050U4 (da)	2014-10-24
DE202010017129U1 (de)	2011-09-14
PL2246321T3 (pl)	2011-12-30
HRP20110745T1 (hr)	2011-12-31
CY1112954T1 (el)	2016-04-13
US20100190859A1 (en)	2010-07-29
EP2308477A1 (en)	2011-04-13
CA2727899A1 (en)	2010-11-23
WO2010085354A1 (en)	2010-07-29
IL214220A0 (en)	2011-08-31
DK2308477T3 (da)	2012-08-13
EP2381767A1 (en)	2011-11-02
EA029262B1 (ru)	2018-02-28
US20100189787A1 (en)	2010-07-29
US20100189790A1 (en)	2010-07-29
CA2799515A1 (en)	2010-11-23
US7855233B2 (en)	2010-12-21
JP2015091813A (ja)	2015-05-14
AR075148A1 (es)	2011-03-09
EP2381767B1 (en)	2016-01-20
US20120263789A1 (en)	2012-10-18
US20140186514A1 (en)	2014-07-03
US20120100189A1 (en)	2012-04-26
EA201170962A1 (ru)	2012-03-30
JP5774495B2 (ja)	2015-09-09
HK1150308A1 (en)	2011-11-25
CZ22819U1 (cs)	2011-10-24
EP2246321A1 (en)	2010-11-03
SI2308477T1 (sl)	2012-09-28
RS52421B (en)	2013-02-28
EP2246321B1 (en)	2011-08-03
RS52033B (en)	2012-04-30
PT2308477E (pt)	2012-08-09
CA2713292C (en)	2011-08-02
ATE518527T1 (de)	2011-08-15
CA2727899C (en)	2013-02-26

Publication	Publication Date	Title
DK2246321T3 (da)	2011-11-21	Rasagilinformulering med forsinket frisætning
EP2637696A4 (en)	2016-07-06	EXTENDED RELEASE COMPOSITION
BRPI1013622A2 (pt)	2016-10-25	cápsula liberadora
BR112012011733A2 (pt)	2019-09-24	formulações de comprimido de liberação imediata
EP2537907A4 (en)	2014-09-03	ANTI-ADHESIVE AGENT COMPOSITION
BRPI1009465A2 (pt)	2015-08-18	Formulação
BRPI0912428A2 (pt)	2016-02-16	formulação farmacêutica sólida de liberação retardada
ZA201300105B (en)	2014-06-25	Creping release agents
GB0907003D0 (en)	2009-06-03	Formulation
EP2661260A4 (en)	2014-05-14	BENZIMIDAZOLE FORMULATIONS WITH MODIFIED RELEASE
EP2405777A4 (en)	2014-05-07	CLOTHING WITH QUICK REMOVAL
EP2707338A4 (en)	2015-01-21	PHOSPHOCOMENT WITH SLOW RELEASE
CO6960544A2 (es)	2014-05-30	Preparación de liberación sostenida
HK1172255A1 (en)	2013-04-19	Extended release preparation
UY33127A (es)	2011-07-29	Formulación de liberación sostenida
GB201307109D0 (en)	2013-05-29	Release coating
IT1399630B1 (it)	2013-04-26	Formulazioni alimentari a lento rilascio
IL218947A0 (en)	2012-07-31	Delayed release compositions
HK1156509A1 (en)	2012-06-15	Delayed release rasagiline formulation
FIU20110119U0 (fi)	2011-03-31	Hidastetusti vapautuva rasagilinikoostumus
FI20100027A0 (fi)	2010-01-27	Laukaisin
FI8827U1 (fi)	2010-08-27	Pikakiinnike
IT1393211B1 (it)	2012-04-11	Dispositivo di innesto rapido
GB0911867D0 (en)	2009-08-19	Multiparticulate formulation
FI20100290A0 (fi)	2010-08-16	Mekaaninen voiman suuntaaja